Literature DB >> 20447046

Obstruction of St. Jude medical valves in the aortic position: plasma transforming growth factor type beta 1 in patients with pannus overgrowth.

Hideki Teshima1, Shuji Fukunaga, Tohru Takaseya, Hiroshi Tomoeda, Hidetoshi Akashi, Shigeaki Aoyagi.   

Abstract

The study investigated the hypothesis that plasma transforming growth factor type beta 1 (TGF-beta1) initiated pannus overgrowth in cases with aortic prosthetic valve dysfunction (PVD). Patients with obstruction of an aortic St. Jude Medical valve in 26 cases (PVD group) and without obstruction in 48 cases (control group) were studied. Plasma TGF-beta1, the intensity of the prothrombin time-international normalized ratio (PT-INR), and the interruption of an oral anticoagulant medicine were conducted. Plasma TGF-beta1 levels in the PVD group (87.7 +/- 29.2 ng/mL) were significantly higher (P < 0.05) than in the control group (73.7 +/- 25.2 ng/mL). The interruption of an oral anticoagulant medicine in 54% of the PVD group versus 12% of the control group was identified (P < 0.001). The mean value of the PT-INR in the PVD group (1.75 +/- 0.30) and control group (1.75 +/- 0.30) was not significantly different (P = 0.82). In conclusion, elevated levels of plasma TGF-beta1 may play a role in pannus overgrowth.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447046     DOI: 10.1111/j.1525-1594.2009.00800.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  10 in total

1.  Dysfunction of mechanical heart valve prosthesis: experience with surgical management in 48 patients.

Authors:  Wei-Guo Ma; Bin Hou; Adiljan Abdurusul; Ding-Xu Gong; Yue Tang; Qian Chang; Jian-Ping Xu; Han-Song Sun
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  Rapid pannus formation after few months of obstructing aortic mechanical prosthesis.

Authors:  Bassel Al-Alao; Urszula Simoniuk; Brian Heron; Haralabos Parissis
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-09-25

3.  Aorta-atria-septum combined incision for aortic valve re-replacement.

Authors:  Yiwei Xu; Xiaofeng Ye; Zhaolong Li; Qiang Zhao
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Recurrent infarctions due to a dome-shaped pannus above the mitral valve prosthesis.

Authors:  Hirofumi Kasahara; Yoshito Inoue; Satoru Suzuki
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

5.  Recurrent pannus formation causing prosthetic aortic valve dysfunction: is excision without valve re-replacement applicable?

Authors:  Ahmad K Darwazah
Journal:  J Cardiothorac Surg       Date:  2012-06-29       Impact factor: 1.637

6.  Rare early prosthesis obstruction after mitral valve replacement: a case report and literature review.

Authors:  Jun Shi; Zhi-xuan Bai; Jia Hu; Ben-gui Zhang; Ying-qiang Guo
Journal:  J Cardiothorac Surg       Date:  2012-07-02       Impact factor: 1.637

7.  Artificial aortic valve dysfunction due to pannus and thrombus - different methods of cardiac surgical management.

Authors:  Stanisław Ostrowski; Anna Marcinkiewicz; Anna Kośmider; Andrzej Walczak; Radosław Zwoliński; Ryszard Jaszewski
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-09-28

8.  Sex-stratified analysis of national trends and outcomes in isolated tricuspid valve surgery.

Authors:  Pranav Chandrashekar; Erin Amanda Fender; Chad J Zack; Yogesh N V Reddy; Courtney E Bennett; Megha Prasad; Mohammed A Al-Hijji; John M Stulak; Virginia M Miller
Journal:  Open Heart       Date:  2018-01-09

9.  Effects of pannus formation on the flow around a bileaflet mechanical heart valve.

Authors:  Woojin Kim; Haecheon Choi; Jihoon Kweon; Dong Hyun Yang; Young-Hak Kim
Journal:  PLoS One       Date:  2020-06-12       Impact factor: 3.240

10.  Degeneration of Bioprosthetic Heart Valves: Update 2020.

Authors:  Alexander E Kostyunin; Arseniy E Yuzhalin; Maria A Rezvova; Evgeniy A Ovcharenko; Tatiana V Glushkova; Anton G Kutikhin
Journal:  J Am Heart Assoc       Date:  2020-09-21       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.